





# AUROPHARMA

29 NOV 2024


## About company

Aurobindo Pharma is an Indian multinational pharmaceutical company that manufactures generic drugs, active pharmaceutical ingredients (APIs), and biosimilars. Founded in 1986, it has a global presence with operations in over 150 countries. The company specializes in various therapeutic segments, including antibiotics, anti-retrovirals, and cardiovascular medicines. Aurobindo Pharma is known for its strong research and development capabilities and large manufacturing capacity.

## Financials



MARKET CAP	₹ 73,981 Cr.
P/E RATIO	20.3
DIVIDEND YIELD	0.36%
ROCE	14.1%
ROE	11.5%
FACE VALUE	1.00
3 YEARS SALES GROWTH	5%
3 YEARS PROFIT GROWTH	-1%



### **Our recommendation**

OPTIONS INSIGHT: BUY AUROPHARMA 1240 CALL BETWEEN 46-47 TARGETS 54-59 STOP LOSS BELOW 38

### **Technical analysis**

Auro Pharma share prices opened higher and sustained at the higher levels. A short-term bullish trend is evident, supported by the fact that the price is currently above the 20-period EMA (1240). The Supertrend indicator is showing a buy signal, with the current price of 1259 INR. The price breaks previous resistance levels of 1255 made on 25 Nov 24. Thus, we recommended AUROPHARMA 1240 Call options.



## **Disclaimer**

I, Ruchi Nahar, SEBI Registered Research Analyst (INH000014544) comply with the qualification and certification requirements under SEBI (Research Analyst) Regulations, 2014. I have qualified CA, CS and MBA, has over 11 years of experience in MNCs, culminating as Head of Finance. I now leverage my expertise to guide stock market investors with strategic insights. All of the views expressed in research reports and recommendations issued by me reflect my personal views about the subject company or companies at the given point of time and I do not receive/accept any kind of compensation, directly or indirectly related to specific recommendations or views expressed in reports issued by me. I/my relatives do not at any point of time of issuing the reports have any material conflict of interest in the subject company neither I was/am/will be engaged in market making activity for the subject company. The investments discussed or views expressed in reports and recommendations issued by me may not be suitable for all investors. The user assumes the entire risk of any use made of this information. I nor any person connected with my report, accepts any liability arising from the use of research document. The recipients of research document should rely on their own investigations and should consult their own financial advisors to determine merit and risks of such investments based on their own risk appetite. Price and value of the investments referred to in this material may go up or down. Past performance is not a guide for future performance. Certain transactions including those involving futures, options and other derivatives as well as non-investment grade securities involve substantial risk and are not suitable for all investors. Reports and recommendations based on technical analysis centres on studying charts of a stock's price movement and trading volume, as opposed to focusing on a company's fundamentals and as such, may not match with a report on a company's fundamentals. Opinions expressed in research reports & recommendations will be based on the current opinions as of the date appearing in research report & recommendations. While I endeavour to update on a reasonable basis the information discussed in research reports, there may be regulatory, compliance, or other reasons that prevent me from doing so. Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice. So far as reports include current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed. Investment in securities market is subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

29 November 2024

